Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | GSK3A | P49840 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.39 |
| ▸ | PIN4 | Q9Y237 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | MGAM | O43451 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | SI | P14410 | 1/20 | 0.39 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.39 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.39 |
| ▸ | LPO | P22079 | 4/20 | 0.37 |
| ▸ | ELANE | P08246 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28985430 | 0.82 | BCHE (0.41) | BCHEALDH1A1LMNAHSD17B10GSK3A | |
| SCHEMBL5569652 | 0.81 | P2RX4 (0.49) | ALDH1A1LMNAHSD17B10PKMGAA | |
| SCHEMBL25249669 | 0.81 | NAAA (0.47) | BCHEALDH1A1LMNATSHRMAPT | |
| SCHEMBL74973 | 0.77 | L3MBTL1 (0.55) | BCHEALDH1A1HSD17B10GAAKMT2A | |
| SCHEMBL16356254 | 0.77 | BCHE (0.41) | BCHEALDH1A1LMNAHSD17B10GSK3A | |
| SCHEMBL5570690 | 0.77 | KMT2A (0.39) | BCHEALDH1A1LMNAGSK3AGSK3B | |
| SCHEMBL31241181 | 0.77 | L3MBTL1 (0.55) | BCHEALDH1A1HSD17B10GAAKMT2A | |
| SCHEMBL14760440 | 0.76 | ALDH1A1 (0.41) | BCHEALDH1A1LMNAHSD17B10GSK3A | |
| SCHEMBL5573133 | 0.74 | ALDH1A1 (0.44) | BCHEALDH1A1LMNAHSD17B10GSK3A | |
| SCHEMBL1678307 | 0.74 | GSK3A (0.57) | BCHEALDH1A1LMNAHSD17B10GSK3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105884866-B | Chemical synthesis method of glatiramer | 漳州未名博欣生物医药有限公司 | 2021-04-20 | — | — | CN | claimed |
| US-20170114339-A1 | Inactivation Method | THERMO FISHER SCIENTIFIC BALTICS UAB (LT) | 2017-04-27 | — | — | US | claimed |
| EP-1806400-B1 | Inactivation method | FERMENTAS UAB (LT) | 2013-03-13 | — | — | EP | claimed |
| US-20070224611-A1 | Inactivation method | FERMENTAS UAB | 2007-09-27 | — | — | US | claimed |
| EP-1806400-A2 | Inactivation method | Fermentas UAB (LT) | 2007-07-11 | — | — | EP | claimed |
| WO-2023123917-A1 | TAQ ENZYME REVERSIBLE MODIFIER, CHEMICALLY MODIFIED TAQ ENZYME, AND PREPARATION METHOD THEREFOR AND PCR KIT THEREOF | 广州达安基因股份有限公司 | 2023-07-06 | — | — | WO | disclosed |
| WO-2023123918-A1 | METHOD FOR IMPROVING ACTIVITY OF CHEMICALLY MODIFIED TAQ ENZYME AND TAQ ENZYME TREATED USING SAME | 广州达安基因股份有限公司 | 2023-07-06 | — | — | WO | disclosed |
| CN-105884866-B | Chemical synthesis method of glatiramer | 漳州未名博欣生物医药有限公司 | 2021-04-20 | — | — | CN | disclosed |
| EP-3186374-A1 | REVERSIBLY INACTIVATED THERMOSTABLE REVERSE TRANSCRIPTASES, COMPOSITIONS AND METHODS FOR USE | Life Technologies Corporation (US) | 2017-07-05 | — | — | EP | disclosed |
| US-20170114339-A1 | Inactivation Method | THERMO FISHER SCIENTIFIC BALTICS UAB (LT) | 2017-04-27 | — | — | US | disclosed |
| US-20160264950-A1 | REVERSIBLY INACTIVATED THERMOSTABLE REVERSE TRANSCRIPTASES, COMPOSITIONS AND METHODS FOR USE | Life Technologies Corporation | 2016-09-15 | — | — | US | disclosed |
| CN-105884866-A | Chemical synthesis method of glatiramer | 漳州博欣生物技术有限公司 | 2016-08-24 | — | — | CN | disclosed |
| WO-2016033116-A1 | REVERSIBLY INACTIVATED THERMOSTABLE REVERSE TRANSCRIPTASES, COMPOSITIONS AND METHODS FOR USE | Life Technologies Corporation (US) | 2016-03-03 | — | — | WO | disclosed |
| US-9273304-B2 | Inactivation method | THERMO FISHER SCIENTIFIC BALTICS UAB (LT) | 2016-03-01 | — | — | US | disclosed |
| EP-1806400-B1 | Inactivation method | FERMENTAS UAB (LT) | 2013-03-13 | — | — | EP | disclosed |
| US-20070224611-A1 | Inactivation method | FERMENTAS UAB | 2007-09-27 | — | — | US | disclosed |
| EP-1806400-A2 | Inactivation method | Fermentas UAB (LT) | 2007-07-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070224611-A1 | Inactivation method | TREH, UNG, NOTUM | BCHE 15/4885ALDH1A1 183/4885LMNA 3330/4885 |
| US-20170114339-A1 | Inactivation Method | TREH, UNG, NOTUM | BCHE 15/4885ALDH1A1 183/4885LMNA 3330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.